Dose Modifications | REVLIMID® (lenalidomide) for MCL
Dose Modification for Myelosuppression
ARV Dosing: Renal Impairment — EACS
Dose modification of cisplatin in renal impairment | Download Table
Treatment modifications/dosing delays and the factors predicating treatment modification should be explicit and clear. If dose
Dose modification scheme for managing palbociclib/placebo-related... | Download Scientific Diagram
Dosing for mNSCLC Treatment | CYRAMZA® (ramucirumab)
Safety and dose modification for patients receiving niraparib - Annals of Oncology
IBRANCE® (palbociclib) Recommended Dose Modifications | Safety Info
ZEJULA (niraparib) Dose Adjustments
IBRANCE® (palbociclib) Recommended Dose Modifications | Safety Info
Dosing & Management – LYNPARZA® (olaparib)
Dosing & Schedule | ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
Dose Modifications in Clinical Trial | REVLIMID® (lenalidomide) for MDS
Dosing for Jakafi in Myelofibrosis | Jakafi HCP
Dose Modifications | REVLIMID® (lenalidomide) for MCL
NOVA Dosing | ZEJULA (niraparib)
Dose modification guidelines for hematological toxicity. | Download Table
Dose modification for neutropenia or thrombocytopenia at day 8 or 15 | Download Table
Dosing and Administration | BALVERSA® (erdafitinib) HCP
HALAVEN® (eribulin mesylate) Injection Dose Modification for Advanced Liposarcoma | HCP
